Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy

Stopped early

Conditions studied: HER2-positive Breast Cancer

In brief

This is a single institution, observational research study in which patients are observed using DWI/DCE MRI imaging before and after receiving neoadjuvant anti-HER2 therapy.

Key facts

Study ID

NCT03738553

Run by

University of Washington

People needed

13

Starts

2013-08-01

Expected to finish

2026-03-01

Last updated by the study team

2026-05-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects at least 18 years of age.
• Have a new diagnosis of invasive breast cancer, clinical stage I - III, HER2 positive.
• Planning to undergo surgical resection plus adjuvant therapy to include an anti-HER2 agent.
• Have tissue block available for review of experimental markers.
• Be a candidate for MRI imaging.
• Be willing to comply with scheduled visits required for the trial.
• Ability to understand and the willingness to sign a written informed consent document.

You may not qualify if…

• Recent therapy for breast cancer prior to baseline MRI.
• Subjects may not receive other investigational agents during the study window for imaging.
• Contraindications for MRI or MRI contrast including severe claustrophobia, history of previous reaction to MRI contrast, renal disease, congestive heart failure, other significant systemic diseases or any metal in their body, including but not limited to: a brain aneurysm clip, implanted neural stimulator, implanted cardiac pacemaker or defibrillator, cochlear implant, ocular foreign body (e.g. metal shavings), other implanted medical devices: (e.g. Swan Ganz catheter), insulin pump, metal shrapnel or bullet.
• Pregnant or nursing.

Where it is running

• Seattle Cancer Care Alliance — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.